46 results about "Vitamin E-TPGS" patented technology

Disclosed herein is an aqueous emulsion. The lipid phase of the emulsion includes a blend of a therapeutically effective concentration of a lipophile, a concentration of Vitamin E TPGS, and a concentration of linoleic acid. The presence of linoleic acid increases the solubilizing affect of Vitamin E TPGS on the lipophile and thus reduces the amount of Vitamin E TPGS that would otherwise be required in the aqueous emulsion.

A liquid Vitamin E TPGS concentrate composition is provided, the concentrate having a significantly higher percentage of TPGS per unit volume than traditional liquid TPGS formulations while providing the TPGS in a liquid form that can be used in softgels or mixed with water to produce desired concentrations for commercial use in supplements, beverages, pharmaceutical preparations, etc.

The invention discloses paclitaxel nano micelle and an application thereof. The paclitaxel nano micelle is prepared from the following components shown in the following (1), (2) or (3): (1) a carrier and paclitaxel, wherein the carrier is a mixture of polyethylene glycol-distearoyl phosphatidyl ethanolamine (PEG-DSPE), D-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS) and dequalinium chloride; (2) a carrier and the paclitaxel, wherein the carrier is a mixture of the PEG-DSPE and the TPGS; and (3) a carrier and the paclitaxel, wherein the carrier is the PEG-DSPE. After the functionalized paclitaxel nano micelle disclosed by the invention is orally taken, the paclitaxel can penetrate through a barrier of gastrointestinal tract, thus the multi-drug resistance (MDR) of drug-resistant breast cancer is overcome. The oral formulation of the functionalized paclitaxel nano micelle disclosed by the invention can avoid the anaphylactic response, can be applied to numerous cancer patients and is also suitable for MDR tumors at the same time, thereby having great advantage compared with the traditional intravenous injection formulation.

A nanoformulation that includes loaded nanoparticles. Each nanoparticle includes a modified chitosan polymer encapsulating at least one vitamin D derivative, at least one vitamin D metabolite, or combinations thereof. The modified chitosan polymer includes chitosan covalently linked to at least one entity selected from the group consisting of fatty acids (omega-3-fattay acids), amino acids, deoxycholic acid, alginate, arginine-alginate, hyaluronic acid, collagen, collagen-hydroxyapatite, poly(lactic-co-glycolic acid) (PLGA), and combinations thereof. A structure includes a medium and the nanoformulation, wherein the nanoparticles are dispersed in the medium. A method of using the nanoformulation to treat a disorder and improve efficacy of current therapies where resistance develop in a patient includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the disorder. A nano-cosmetic formulation, comprising a cosmetic includes the nanoformulation, wherein the modified chitosan polymer encapsulates the at least one vitamin D derivative, and wherein the at least one vitamin D derivative encompasses 0.1 to 20.0 wt % of the nano-cosmetic formulation's total weight.

The invention discloses a nano-particle containing docetaxel and vitamin E TPGS (d-alpha tocopheryl polyethylene glycol 1000 succinate) and a preparation method thereof. The nano-particle containing docetaxel and vitamin E TPGS comprises the following components in parts by weight: 2-10 parts of docetaxel, 1-15 parts of vitamin E TPGS, 20-65 parts of albumin, 5-50 parts of cryoprotectant, and 2-20 parts of acidic buffer salt. Relative to an existing docetaxel commercial preparation, the nano-particle containing docetaxel and vitamin E TPGS is good in drug entrapping performance, small in toxic and side effect, high in stability, good in anti-tumor curative effect and convenient to administer; the preparation method is simple, and the production cost is low.

The invention belongs to the technical field of biomedicines, and relates to a paclitaxel entrapped polymeric micelle for treating tumors, and a preparation method thereof. The preparation method comprises the following steps: preparing paclitaxel PEG-PLA/Vitamin E-TPGS mixed micelle through adopting a film dispersion technology, and entrapping paclitaxel into the hydrophobic core of the mixed micelle by using the mixed micelle composed of PEG-PLA and Vitamin E-TPGS as a carrier. The prepared paclitaxel paclitaxel PEG-PLA/Vitamin E-TPGS mixed micelle can effectively increase the solubility of paclitaxel and substantially improves the paclitaxel load of a micelle system to reach 35% (w/w), and Vitamin E-TPGS in the mixed micelle system has a P-gp efflux inhibition biologic function, and can efficiently reverse the multidrug resistance of tumors in order to improve the tumor treatment effect. The mixed micelle does not contain Tween80 or ethanol; and compared with commercial paclitaxel injections, the above preparation provided by the invention has the advantages of no allergy of commercial preparations, reduction of toxic side effects, and increase of the safety of clinic application.

The invention provides a nano-micelle drug carrier based on a vitamin E derivative, a nano-micelle drug composition as well as a preparation method and application of the nano-micelle drug composition. The nano-micelle drug carrier based on the vitamin E derivative is a nano-micelle formed by D-alpha-tocopherol polyethylene glycol 1000 succinate, D-alpha-tocopherol polyethylene glycol 2000 succinate and alpha-tocopherol succinate; and the carrier entraps a hydrophobic anti-tumor drug to obtain the nano-micelle drug composition. The D-alpha-tocopherol polyethylene glycol 1000 succinate, D-alpha-tocopherol polyethylene glycol 2000 succinate and alpha-tocopherol succinate are matched with one another and cooperate, so that the formed nano-micelle is good in stability, is small and uniform in grain size, improves drug encapsulation efficiency, has relatively good P-glycoprotein inhibiting ability, has good anti-tumor effect, is small in toxicity to normal cells and has good biocompatibility. The preparation method is simple and is wide in application prospect.

A pharmaceutical composition for the oral administration of a therapeutic compound of formula (I), comprising granules that comprise at least therapeutic compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof; at least one non-ionic surfactant that is Vitamin E-TPGS in an amount ranging from about 15 to about 80% by weight of the composition; and at least one a dissolution enhancing agent selected from polyethylene glycol, polyethylene oxide, and any combination of the foregoing; processes for making such pharmaceutical compositions; a kit comprising such pharmaceutical composition and the instructions for administration thereof; and related uses and methods of treatment.

The invention discloses application of vitamin E TPGS (d-alpha tocopheryl polyethylene glycol 1000 succinate) in preparing porous drug carrier particles, a method for preparing porous drug carrier particles, and the porous drug carrier particles. The method comprises the following steps: dissolving vitamin E TPGS, medicines and organic macromolecular polymer, such as PLGA (poly(lactic-co-glycolic acid)), in an organic solvent; emulsifying, removing the organic solvent in a volatizing manner to obtain the drug-loaded porous drug carrier particles with a porous structure on the surface. The porous drug carrier particles have the characteristics of small toxicity, high target, high encapsulation rate, porosity and drug in-vitro release acceleration, can be used for inhibiting P-gp induced drug transportation due to TPGS, so that the multi-drug resistance effect of an administrated object can be inhibited; furthermore, the porous drug carrier particles are utilized in administration, and the drug utilization is high, so that the dosage can be effectively reduced, and side effects can be further reduced.

The invention discloses an amphiphilic anti-cancer drug compound modified by a water-soluble vitamin E derivative. The amphiphilic anti-cancer drug compound has the structure of the following formula I or II. The anti-cancer drug active part camptothecin or camptothecin derivative, and amphiphilic part water-soluble vitamin E alkoxy polyethylene glycol ester or amide are covalently bonded by linking groups to form the amphiphilic anti-cancer drug compound. The invention further relates to a preparation, a preparation method and an application for the medicine compound.

This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.

The invention relates to a preparation method and application of vitamin E molecularly imprinted polymer. According to the preparation method, acetone is adopted as an organic solvent, vitamin E, acrylamide, ethylene glycol dimethacrylate and azodiisobutyronitrile are adopted as raw materials, and the molecularly imprinted polymer is obtained through a reaction at 60-70 DEG C under the conditionsof oxygen isolation. It is shown through experiment that the polymer has specific adsorption properties for vitamin E, and vitamin E can be identified precisely and separated from a complex system, and the successful synthesis of the molecularly imprinted polymer is of great significance to the industrial separation and purification of vitamin E.

Topical drug delivery systems for ophthalmic use including mixed nanomicellar formulations of water-insoluble drugs and methods of treating diseases affecting the posterior ocular segments are disclosed. In an embodiment, an aqueous ophthalmic solution includes nanomicelles in a physiologically acceptable buffer, having a pH of 5.0 to 8.0, wherein a corticosteroid at a concentration from about 0.01 % w/v to about 1.00 % w/v is solubilized through entrapment in a mixed micellar hydrophobic core with a corona composed of hydrophilic chains extending from the hydrophobic core, wherein the nanomicelles comprise vitamin E TPGS at a concentration ranging from about 3.0 % w/v to about 5.0 % w/v stabilized with octoxynol-40 at a concentration ranging from about 1.0 % w/v to about 3.0 % w/v.

The invention discloses D-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS)-b-(polylactide (PLA)-ran-polyglycolide (PGA)) copolymer and a preparation method and application thereof. Structural formulas of the copolymer are shown as a formula I and/or a formula II, wherein n is 20 to 140, A+B+... is 2 to 690, and a+b+... is 2 to 840. The preparation method comprises the following steps of: putting 2 to 95 mass percent of lactide monomers, 2 to 95 mass percent of glycolide monomers and 3 to 40 mass percent of D-alpha-tocopherol polyethylene glycol 1000 succinate serving as raw materials into a reactor; adding a catalyst which accounts for 0.1 to 1 percent based on the total mass of the raw materials; and reacting in the absence of oxygen at the temperature of between 140 and 160 DEG C for 12 to 20 hours to obtain the TPGS-b-(PLA-ran-PGA) copolymer. The TPGS-b-(PLA-ran-PGA) copolymer prepared by the invention has high biocompatibility and biodegradability, and is applied to the fields of medicinal preparations and tissue engineering, particularly the field of medicinal preparations for resisting and treating tumor.

The invention discloses a preparation method of a solubilizing agent, and belongs to the technical field of solubilizing agents. The method comprises the steps that to-be-purified vitamin E-polyethylene glycol-succinate is dissolved in an organic solvent, heated to be dissolved, washed for 1-5 times with saline water, dried with a drying agent after washing, and filtered after drying, the organicsolvent is steamed out to obtain vitamin E polyethylene glycol succinic acid ester with low content of polyethylene glycol; the organic solvent is selected from ethyl acetate, butyl acetate or methylbenzene; the content of the polyethylene glycol in the to-be-purified vitamin E-polyethylene glycol-succinate is 5-30% by weight, and the content of the vitamin E-succinate is less than 0.5% by weight.The preparation method of the solubilizing agent has the advantages that simple technology and low cost are used to purify the crude vitamin E-polyethylene glycol-succinate, the operation is simple,no special equipment is needed, the polyethylene glycol in the product can be effectively removed and controlled in a certain range, and the vitamin E succinate is reserved.

The invention belongs to the field of veterinary drug preparations, particularly belongs to the technical field of fat-soluble vitamin injection and relates to vitamin ADE microemulsion injecta for veterinary use and a preparation method of the vitamin ADE microemulsion injecta. The vitamin ADE microemulsion injecta for the veterinary use is prepared from the following raw materials in parts by weight: 5 to 10 parts of vitamin A palmitate, 0.1 to 1 part of vitamin D 3 oil, 20 to 50 parts of vitamin E acetate, 0.5 to 1 part of BHA (Butylated Hydroxyanisole), 0.5 to 1 part of BHT (Butylated Hydroxytoluene), 1 to 2 parts of phenylcarbinol, 2 to 10 parts of Tween 80, 10 to 30 parts of absolute ethyl alcohol and 10 to 60 parts of soybean oil for injection. The invention also provides the preparation method of the injecta. According to the preparation method of the vitamin ADE microemulsion injecta, disclosed by the invention, vitamin A, vitamin D and vitamin E are compounded for use; the latest international recommended dose of vitamin is used as the basis of the content of a main drug, grease is selected as a solvent according to the solubility property of the vitamin and is compounded with a certain amount of a surfactant and a cosurfactant, and thus a clear vitamin ADE injecta is obtained; the hydrophilicity and the dispersibility of the product are increased, rapid absorption of an organism is facilitated and the bioavailability is improved.

The invention discloses a bazedoxifene acetate composition with excellent properties. The composition comprises bazedoxifene acetate, polyethylene glycol (PEG) 6000-8000 and vitamin E tocopherol polyethylene glycol succinate (TPGS), wherein a solid solution and/or solid sol is formed by polyethylene glycol (PEG) 6000-8000 and vitamin E TPGS, and bazedoxifene acetate is dispersed into the solid solution and/or solid sol. The composition is high in chemical stability and medicine release speed.

The invention relates to application of a fat emulsion injection using a vitamin K1. Particularly, the invention relates to an emulsion composition comprising the vitamin K1, soybean oil, phospholipid, glycerin and water. The emulsion composition is prepared by processes of preparation of a aqueous phase, preparation of an oil phase, preparation of a coarse emulsion, high-pressure emulsification,hot press sterilization and the like. The invention further relates to a method for preparing the emulsion composition and pharmaceutical application of the emulsion composition. The emulsion injection is used for insufficiency of the vitamin K or coagulation disorder diseases caused by dyssynthesis of coagulation factors II, VII, IX and X, which are generated due to pharmacological intervention interfering the activity of the vitamin K. The emulsion composition disclosed by the invention shows one or various technical effects as shown in the specification.

The present invention relates to stable solid formulations of vitamin D₃ and to processes for preparation of the same. The present invention provides stabilized compositions comprising vitamin D₃ at least one lipophilic dispersant, one or more antioxidants, at least one adsorbent and one or more pharmaceutically acceptable excipients and further coated with a barrier coating.

A method for forming an emulsion containing a cannabinoid includes the steps of first providing a composition comprising water, vitamin E TPGS, a cannabinoid, and a carrier oil, in a high pressure container. The composition is initially opaque. The composition is then heated to a temperature between 50-120 degrees Celsius, the heating increasing the pressure in the high pressure container to greater than 1 ATM. The high pressure container is then cooled, while mixing, until the composition turns clear, and a micelle water emulsion is formed with particles under 100 nm in particle size.

Compositions including Portulaca extract and a vitamin C derivative selected from ascorbyl glucoside (ASG), magnesium ascorbyl phosphate an ethyl ascorbic acid. The compositions can be employed as an inhibitor to melanin formation and used as an additive to a cosmetic or pharmaceutical formulation.

Provided is a composition comprising: a polysorbate, vitamin E TPGS, a cannabinoid, and an antioxidant. Also provided is a use of the composition for oral consumption and/or topical application and a method of making the composition.

The invention discloses a water-soluble coagulant drug vitamin k2 solid-state complex and a preparation method thereof, and belongs to the technical field of medicines. The product is a solid-state complex of mono-[6-(diethylenetriamine)-6-deoxy]-[beta]-cyclodextrin and vitamin K2 at a mixing ratio of 2 to 1. The mono-[6-(diethylenetriamine)-6-deoxy]-[beta]-cyclodextrin is obtained by adding mono-(6-o-6-p-toluenesulfonyl)-[beta]-cyclodextrin to diethylenetriamine, conducting a reaction in a mode of dissolving and increasing temperature in a nitrogen atmosphere, adding acetone after most diethylenetriamine is distilled so as to obtain a crude product, dissolving the crude product in a water and separating the dissolved product so as to obtain the mono-[6-(diethylenetriamine)-6-deoxy]-[beta]-cyclodextrin. A vitamin K2 acetone solution is added to a mono-[6-(diethylenetriamine)-6-deoxy]-[beta]-cyclodextrin water solution, and it conducts stirring at 35-40 DEG C in a sealed mode for 4.5-5.5 days so as to remove acetone and vitamin K2 failing to participate in inclusion. The obtained product (the solid-state complex) is low in toxicity; and the solubility of the vitamin K2, through inclusion, in water is increased by 110 times, and the product, as a vitamin K2 substitute, is applicable to the clinical field.